
Karin Tarte

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5654879/publications.pdf Version: 2024-02-01



Κλαινι Τλατε

#	Article	IF	CITATIONS
1	BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood, 2004, 103, 3148-3157.	1.4	488
2	Single-Cell Analysis Reveals Fibroblast Clusters Linked to Immunotherapy Resistance in Cancer. Cancer Discovery, 2020, 10, 1330-1351.	9.4	424
3	Clinical-grade production of human mesenchymal stromal cells: occurrence of aneuploidy without transformation. Blood, 2010, 115, 1549-1553.	1.4	403
4	Immunological characterization of multipotent mesenchymal stromal cells—The International Society for Cellular Therapy (ISCT) working proposal. Cytotherapy, 2013, 15, 1054-1061.	0.7	364
5	Risk of tumorigenicity in mesenchymal stromal cell–based therapies—Bridging scientific observations and regulatory viewpoints. Cytotherapy, 2013, 15, 753-759.	0.7	312
6	High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial. Leukemia, 2014, 28, 2367-2375.	7.2	281
7	Human mesenchymal stem cells isolated from bone marrow and lymphoid organs support tumor B-cell growth: role of stromal cells in follicular lymphoma pathogenesis. Blood, 2007, 109, 693-702.	1.4	228
8	Loss of the HVEM Tumor Suppressor in Lymphoma and Restoration by Modified CAR-T Cells. Cell, 2016, 167, 405-418.e13.	28.9	204
9	Good Manufacturing Practices Production of Mesenchymal Stem/Stromal Cells. Human Gene Therapy, 2011, 22, 19-26.	2.7	196
10	Survival and Proliferation Factors of Normal and Malignant Plasma Cells. International Journal of Hematology, 2003, 78, 106-113.	1.6	195
11	Gene expression profiling of plasma cells and plasmablasts: toward a better understanding of the late stages of B-cell differentiation. Blood, 2003, 102, 592-600.	1.4	190
12	Clinical-Grade Mesenchymal Stromal Cells Produced Under Various Good Manufacturing Practice Processes Differ in Their Immunomodulatory Properties: Standardization of Immune Quality Controls. Stem Cells and Development, 2013, 22, 1789-1801.	2.1	186
13	Early Expansion of Circulating Granulocytic Myeloid-derived Suppressor Cells Predicts Development of Nosocomial Infections in Patients with Sepsis. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 315-327.	5.6	184
14	A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts. Lancet Oncology, The, 2018, 19, 549-561.	10.7	165
15	Characterization of intratumoral follicular helper T cells in follicular lymphoma: role in the survival of malignant B cells. Leukemia, 2012, 26, 1053-1063.	7.2	163
16	Comparison of gene expression profiling between malignant and normal plasma cells with oligonucleotide arrays. Oncogene, 2002, 21, 6848-6857.	5.9	157
17	Identifying intercellular signaling genes expressed in malignant plasma cells by using complementary DNA arrays. Blood, 2001, 98, 771-780.	1.4	154
18	JAK2 tyrosine kinase inhibitor tyrphostin AG490 downregulates the mitogen-activated protein kinase (MAPK) and signal transducer and activator of transcription (STAT) pathways and induces apoptosis in myeloma cells. British Journal of Haematology, 2000, 109, 823-828.	2.5	146

Karin Tarte

#	Article	IF	CITATIONS
19	Follicular lymphoma cell niche: identification of a preeminent IL-4-dependent TFH–B cell axis. Leukemia, 2010, 24, 2080-2089.	7.2	133
20	Mesenchymal stromal cells orchestrate follicular lymphoma cell niche through the CCL2-dependent recruitment and polarization of monocytes. Blood, 2012, 119, 2556-2567.	1.4	133
21	Impaired efferocytosis and neutrophil extracellular trap clearance by macrophages in ARDS. European Respiratory Journal, 2018, 52, 1702590.	6.7	132
22	Unique B Cell Differentiation Profile in Tolerant Kidney Transplant Patients. American Journal of Transplantation, 2014, 14, 144-155.	4.7	131
23	Characterization of a Transitional Preplasmablast Population in the Process of Human B Cell to Plasma Cell Differentiation. Journal of Immunology, 2011, 187, 3931-3941.	0.8	123
24	T-cell defect in diffuse large B-cell lymphomas involves expansion of myeloid-derived suppressor cells. Blood, 2016, 128, 1081-1092.	1.4	120
25	Immunofibroblasts are pivotal drivers of tertiary lymphoid structure formation and local pathology. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 13490-13497.	7.1	115
26	IL-6 supports the generation of human long-lived plasma cells in combination with either APRIL or stromal cell-soluble factors. Leukemia, 2014, 28, 1647-1656.	7.2	109
27	DC-SIGN–expressing macrophages trigger activation of mannosylated IgM B-cell receptor in follicular lymphoma. Blood, 2015, 126, 1911-1920.	1.4	109
28	GenomicScape: An Easy-to-Use Web Tool for Gene Expression Data Analysis. Application to Investigate the Molecular Events in the Differentiation of B Cells into Plasma Cells. PLoS Computational Biology, 2015, 11, e1004077.	3.2	109
29	A catalytic-independent role for the LUBAC in NF-κB activation upon antigen receptor engagement and in lymphoma cells. Blood, 2014, 123, 2199-2203.	1.4	105
30	CXCR4 Expression Functionally Discriminates Centroblasts versus Centrocytes within Human Germinal Center B Cells. Journal of Immunology, 2009, 182, 7595-7602.	0.8	102
31	High rate of TNFRSF14 gene alterations related to 1p36 region in de novo follicular lymphoma and impact on prognosis. Leukemia, 2012, 26, 559-562.	7.2	97
32	Role of the tumor microenvironment in regulating apoptosis and cancer progression. Cancer Letters, 2016, 378, 150-159.	7.2	96
33	Germinal center reentries of BCL2-overexpressing B cells drive follicular lymphoma progression. Journal of Clinical Investigation, 2014, 124, 5337-5351.	8.2	96
34	IL-2 Requirement for Human Plasma Cell Generation: Coupling Differentiation and Proliferation by Enhancing MAPK–ERK Signaling. Journal of Immunology, 2012, 189, 161-173.	0.8	93
35	Mutant EZH2 Induces a Pre-malignant Lymphoma Niche by Reprogramming the Immune Response. Cancer Cell, 2020, 37, 655-673.e11.	16.8	93
36	Comparative Study of Immune Regulatory Properties of Stem Cells Derived from Different Tissues. Stem Cells and Development, 2013, 22, 2990-3002.	2.1	89

#	Article	IF	CITATIONS
37	Limited Acquisition of Chromosomal Aberrations in Human Adult Mesenchymal Stromal Cells. Cell Stem Cell, 2012, 10, 9-10.	11.1	87
38	Preclinical Development of a Bispecific Antibody that Safely and Effectively Targets CD19 and CD47 for the Treatment of B-Cell Lymphoma and Leukemia. Molecular Cancer Therapeutics, 2018, 17, 1739-1751.	4.1	87
39	SARS-CoV-2-Induced ARDS Associates with MDSC Expansion, Lymphocyte Dysfunction, and Arginine Shortage. Journal of Clinical Immunology, 2021, 41, 515-525.	3.8	87
40	The yin and the yang of follicular lymphoma cell niches: Role of microenvironment heterogeneity and plasticity. Seminars in Cancer Biology, 2014, 24, 23-32.	9.6	82
41	IL-4/CXCL12 loop is a key regulator of lymphoid stroma function in follicular lymphoma. Blood, 2017, 129, 2507-2518.	1.4	80
42	Monocytes and T cells cooperate to favor normal and follicular lymphoma B-cell growth: role of IL-15 and CD40L signaling. Leukemia, 2012, 26, 139-148.	7.2	77
43	IL-2 imprints human naive B cell fate towards plasma cell through ERK/ELK1-mediated BACH2 repression. Nature Communications, 2017, 8, 1443.	12.8	77
44	Functional Alteration of the Lymphoma Stromal Cell Niche by the Cytokine Context: Role of Indoleamine-2,3 Dioxygenase. Cancer Research, 2009, 69, 3228-3237.	0.9	76
45	CD40 Ligand Protects from TRAIL-Induced Apoptosis in Follicular Lymphomas through NF-ήB Activation and Up-Regulation of c-FLIP and Bcl-xL. Journal of Immunology, 2008, 181, 1001-1011.	0.8	75
46	Dendritic cell-based vaccine: a promising approach for cancer immunotherapy. Leukemia, 1999, 13, 653-663.	7.2	71
47	Sustained activation of the Aryl hydrocarbon Receptor transcription factor promotes resistance to BRAF-inhibitors in melanoma. Nature Communications, 2018, 9, 4775.	12.8	70
48	Enhanced Indoleamine 2,3â€Dioxygenase Activity in Patients with Severe Sepsis and Septic Shock. Journal of Infectious Diseases, 2010, 201, 956-966.	4.0	66
49	Tumor necrosis factor is a survival and proliferation factor for human myeloma cells. European Cytokine Network, 1999, 10, 65-70.	2.0	66
50	Cell-Cycle-Dependent Reconfiguration of the DNA Methylome during Terminal Differentiation of Human B Cells into Plasma Cells. Cell Reports, 2015, 13, 1059-1071.	6.4	65
51	Immunoregulatory properties of clinical grade mesenchymal stromal cells: evidence, uncertainties, and clinical application. Stem Cell Research and Therapy, 2013, 4, 64.	5.5	61
52	CD10 delineates a subset of human IL-4 producing follicular helper T cells involved in the survival of follicular lymphoma B cells. Blood, 2015, 125, 2381-2385.	1.4	61
53	Neutrophils trigger a NF-IºB dependent polarization of tumor-supportive stromal cells in germinal center B-cell lymphomas. Oncotarget, 2015, 6, 16471-16487.	1.8	60
54	Functional Regulatory T Cells Are Collected in Stem Cell Autografts by Mobilization with High-Dose Cyclophosphamide and Granulocyte Colony-Stimulating Factor. Journal of Immunology, 2006, 176, 6631-6639.	0.8	59

#	Article	IF	CITATIONS
55	Generation of polyclonal plasmablasts from peripheral blood B cells: a normal counterpart of malignant plasmablasts. Blood, 2002, 100, 1113-22.	1.4	59
56	Self-Restrained B Cells Arise following Membrane IgE Expression. Cell Reports, 2015, 10, 900-909.	6.4	57
57	Microarray-based understanding of normal and malignant plasma cells. Immunological Reviews, 2006, 210, 86-104.	6.0	56
58	Frontline Science: HMGB1 induces neutrophil dysfunction in experimental sepsis and in patients who survive septic shock. Journal of Leukocyte Biology, 2017, 101, 1281-1287.	3.3	55
59	Aryl hydrocarbon receptor–dependent enrichment of a megakaryocytic precursor with a high potential to produce proplatelets. Blood, 2016, 127, 2231-2240.	1.4	54
60	Extensive characterization of dendritic cells generated in serum-free conditions: regulation of soluble antigen uptake, apoptotic tumor cell phagocytosis, chemotaxis and T cell activation during maturation in vitro. Leukemia, 2000, 14, 2182-2192.	7.2	51
61	Integrated transcriptomic, phenotypic, and functional study reveals tissue-specific immune properties of mesenchymal stromal cells. Stem Cells, 2020, 38, 146-159.	3.2	50
62	Liposuction Preserves the Morphological Integrity of the Microvascular Network: Flow Cytometry and Confocal Microscopy Evidence in a Controlled Study. Aesthetic Surgery Journal, 2016, 36, 609-618.	1.6	49
63	Impairment of B-lymphocyte differentiation induced by dual triggering of the B-cell antigen receptor and CD40 in advanced HIV-1-disease. Aids, 1998, 12, 1437-1449.	2.2	47
64	Stromal Cell Contribution to Human Follicular Lymphoma Pathogenesis. Frontiers in Immunology, 2012, 3, 280.	4.8	46
65	Mesenchymal stromal cell variables influencing clinical potency: the impact of viability, fitness, route of administration and host predisposition. Cytotherapy, 2021, 23, 368-372.	0.7	45
66	Human t(14;18)positive germinal center B cells: a new step in follicular lymphoma pathogenesis?. Blood, 2014, 123, 3462-3465.	1.4	44
67	Follicular lymphoma triggers phenotypic and functional remodeling of the human lymphoid stromal cell landscape. Immunity, 2021, 54, 1788-1806.e7.	14.3	43
68	Soluble programmed death-ligand 1 as a prognostic biomarker for overall survival in patients with diffuse large B-cell lymphoma: a replication study and combined analysis of 508 patients. Leukemia, 2017, 31, 988-991.	7.2	41
69	Emergence of long-lived autoreactive plasma cells in the spleen of primary warm auto-immune hemolytic anemia patients treated with rituximab. Journal of Autoimmunity, 2015, 62, 22-30.	6.5	40
70	Brief Report: Proteasomal Indoleamine 2,3-Dioxygenase Degradation Reduces the Immunosuppressive Potential of Clinical Grade-Mesenchymal Stromal Cells Undergoing Replicative Senescence. Stem Cells, 2017, 35, 1431-1436.	3.2	40
71	Hypoxia Differentially Modulates the Genomic Stability of Clinical-Grade ADSCs and BM-MSCs in Long-Term Culture. Stem Cells, 2015, 33, 3608-3620.	3.2	39
72	Combination lenalidomideâ€rituximab immunotherapy activates antiâ€tumour immunity and induces tumour cell death by complementary mechanisms of action in follicular lymphoma. British Journal of Haematology, 2019, 185, 240-253.	2.5	39

#	Article	IF	CITATIONS
73	Evidence against KSHV infection in the pathogenesis of multiple myeloma. Virus Research, 1998, 57, 197-202.	2.2	37
74	Immune Dysfunction After Cardiac Surgery with Cardiopulmonary Bypass. Shock, 2015, 44, 228-233.	2.1	37
75	Microenvironment signaling driving lymphomagenesis. Current Opinion in Hematology, 2018, 25, 335-345.	2.5	36
76	COX-2–Independent Effects of Celecoxib Sensitize Lymphoma B Cells to TRAIL-Mediated Apoptosis. Clinical Cancer Research, 2014, 20, 2663-2673.	7.0	35
77	Anti-CD20 IgA can protect mice against lymphoma development: evaluation of the direct impact of IgA and cytotoxic effector recruitment on CD20 target cells. Haematologica, 2012, 97, 1686-1694.	3.5	34
78	Lectin-like transcript 1 is a marker of germinal center-derived B-cell non-Hodgkin's lymphomas dampening natural killer cell functions. Oncolmmunology, 2015, 4, e1026503.	4.6	33
79	Labeling of mesenchymal stromal cells with iron oxide–poly(l-lactide) nanoparticles for magnetic resonance imaging: uptake, persistence, effects on cellular function and magnetic resonance imaging properties. Cytotherapy, 2011, 13, 962-975.	0.7	30
80	Loss of ILâ€22 inhibits autoantibody formation in collagenâ€induced arthritis in mice. European Journal of Immunology, 2016, 46, 1404-1414.	2.9	30
81	CXCR5 and ICOS expression identifies a CD8 T-cell subset with TFH features in Hodgkin lymphomas. Blood Advances, 2018, 2, 1889-1900.	5.2	30
82	Adipose mesenchymal stromal cells: Definition, immunomodulatory properties, mechanical isolation and interest for plastic surgery. Annales De Chirurgie Plastique Et Esthetique, 2019, 64, 1-10.	0.6	29
83	Mesenchymal stromal cells for systemic sclerosis treatment. Autoimmunity Reviews, 2021, 20, 102755.	5.8	28
84	Localized Store-Operated Calcium Influx Represses CD95-Dependent Apoptotic Effects of Rituximab in Non-Hodgkin B Lymphomas. Journal of Immunology, 2015, 195, 2207-2215.	0.8	26
85	Fam72a enforces error-prone DNA repair during antibody diversification. Nature, 2021, 600, 329-333.	27.8	26
86	The Bcl-2 family member Bfl-1/A1 is strongly repressed in normal and malignant plasma cells but is a potent anti-apoptotic factor for myeloma cells. British Journal of Haematology, 2004, 125, 373-382.	2.5	25
87	B7-1 and 4-1BB ligand expression on a myeloma cell line makes it possible to expand autologous tumor-specific cytotoxic T cells in vitro. Experimental Hematology, 2007, 35, 443-453.	0.4	25
88	NK cell activation and recovery of NK cell subsets in lymphoma patients after obinutuzumab and lenalidomide treatment. Oncolmmunology, 2018, 7, e1409322.	4.6	25
89	An open-label phase 1b study of obinutuzumab plus lenalidomide in relapsed/refractory follicular B-cell lymphoma. Blood, 2018, 132, 1486-1494.	1.4	25
90	A gp130 interleukin-6 transducer-dependent SCID model of human multiple myeloma. Blood, 1998, 91, 4727-37.	1.4	25

#	Article	IF	CITATIONS
91	Induced expression of B7-1 on myeloma cells following retroviral gene transfer results in tumor-specific recognition by cytotoxic T cells. Journal of Immunology, 1999, 163, 514-24.	0.8	25
92	Role of the microenvironment across histological subtypes of NHL. Hematology American Society of Hematology Education Program, 2017, 2017, 610-617.	2.5	22
93	Venoarterial extracorporeal membrane oxygenation induces early immune alterations. Critical Care, 2021, 25, 9.	5.8	22
94	Pan-HDAC Inhibitors Restore PRDM1 Response to IL21 in CREBBP-Mutated Follicular Lymphoma. Clinical Cancer Research, 2019, 25, 735-746.	7.0	21
95	Characterization of human FCRL4-positive B cells. PLoS ONE, 2017, 12, e0179793.	2.5	21
96	Targeting netrinâ€1/ <scp>DCC</scp> interaction in diffuse large Bâ€cell and mantle cell lymphomas. EMBO Molecular Medicine, 2016, 8, 96-104.	6.9	19
97	Bone marrow mesenchymal stromal cell (MSC) gene profiling in chronic myeloid leukemia (CML) patients at diagnosis and in deep molecular response induced by tyrosine kinase inhibitors (TKIs). Leukemia Research, 2017, 60, 94-102.	0.8	19
98	Regulatory myeloid cells: an underexplored continent in B-cell lymphomas. Cancer Immunology, Immunotherapy, 2017, 66, 1103-1111.	4.2	19
99	Follicular lymphoma dynamics. Advances in Immunology, 2021, 150, 43-103.	2.2	19
100	Extracellular vesicles shed by follicular lymphoma B cells promote polarization of the bone marrow stromal cell niche. Blood, 2021, 138, 57-70.	1.4	19
101	Mass Cytometry Identifies Expansion of T-bet+ B Cells and CD206+ Monocytes in Early Multiple Sclerosis. Frontiers in Immunology, 2021, 12, 653577.	4.8	19
102	The Chronic Lymphocytic Leukemia Clone Disrupts the Bone Marrow Microenvironment. Stem Cells and Development, 2014, 23, 2972-2982.	2.1	18
103	Comparison of two enzymatic immunoassays, high resolution mass spectrometry method and radioimmunoassay for the quantification of human plasma histamine. Journal of Pharmaceutical and Biomedical Analysis, 2016, 118, 307-314.	2.8	18
104	A novel 3D culture model recapitulates primary FL B-cell features and promotes their survival. Blood Advances, 2021, 5, 5372-5386.	5.2	18
105	Comparative immune profiling of acute respiratory distress syndrome patients with or without SARS-CoV-2 infection. Cell Reports Medicine, 2021, 2, 100291.	6.5	17
106	Flow Cytometric Detection and Isolation of Human Tonsil or Lymph Node T Follicular Helper Cells. Methods in Molecular Biology, 2015, 1291, 163-173.	0.9	16
107	Indoleamine 2,3-dioxygenase activity as a potential biomarker of immune suppression during visceral leishmaniasis. Innate Immunity, 2013, 19, 564-568.	2.4	15
108	ROQUIN/RC3H1 Alterations Are Not Found in Angioimmunoblastic T-Cell Lymphoma. PLoS ONE, 2013, 8, e64536.	2.5	15

#	Article	IF	CITATIONS
109	Effects of a Ceramic Biomaterial on Immune Modulatory Properties and Differentiation Potential of Human Mesenchymal Stromal Cells of Different Origin. Tissue Engineering - Part A, 2015, 21, 767-781.	3.1	15
110	Consensus International Council for Commonality in Blood Banking Automation–International Society for Cell & Gene Therapy statement on standard nomenclature abbreviations for the tissue of origin of mesenchymal stromal cells. Cytotherapy, 2021, 23, 1060-1063.	0.7	15
111	Impact of B cell/lymphoid stromal cell crosstalk in B-cell physiology and malignancy. Immunology Letters, 2019, 215, 12-18.	2.5	14
112	Integrative Analysis of Cell Crosstalk within Follicular Lymphoma Cell Niche: Towards a Definition of the FL Supportive Synapse. Cancers, 2020, 12, 2865.	3.7	14
113	Safety and preliminary efficacy of allogeneic bone marrow-derived multipotent mesenchymal stromal cells for systemic sclerosis: a single-centre, open-label, dose-escalation, proof-of-concept, phase 1/2 study. Lancet Rheumatology, The, 2022, 4, e91-e104.	3.9	14
114	Epigenetic mechanisms driving tumor supportive microenvironment differentiation and function: a role in cancer therapy?. Epigenomics, 2020, 12, 157-169.	2.1	13
115	Kaposi's sarcoma-associated herpesvirus and multiple myeloma: lack of criteria for causality. Blood, 1999, 93, 3159-63; discussion 3163-4.	1.4	13
116	Beneficial effects of citrulline enteral administration on sepsis-induced T cell mitochondrial dysfunction. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	7.1	13
117	Lenalidomide Enhance CAR T-Cells Response in Patients with Refractory/Relapsed Large B Cell Lymphoma Experiencing Progression after Infusion. Blood, 2020, 136, 16-17.	1.4	12
118	Follicular lymphoma: Stateâ€ofâ€ŧheâ€art ICML workshop in Lugano 2015. Hematological Oncology, 2017, 35, 397-407.	1.7	11
119	Lenalidomide triggers T-cell effector functions in vivo in patients with follicular lymphoma. Blood Advances, 2021, 5, 2063-2074.	5.2	11
120	Molecular Networking for Drug Toxicities Studies: The Case of Hydroxychloroquine in COVID-19 Patients. International Journal of Molecular Sciences, 2022, 23, 82.	4.1	11
121	Designed Surface Topographies Control ICAM-1 Expression in Tonsil-Derived Human Stromal Cells. Frontiers in Bioengineering and Biotechnology, 2018, 6, 87.	4.1	10
122	B cell/stromal cell crosstalk in health, disease, and treatment: Follicular lymphoma as a paradigm. Immunological Reviews, 2021, 302, 273-285.	6.0	10
123	The class-specific BCR tonic signal modulates lymphomagenesis in ac-mycderegulation transgenic model. Oncotarget, 2014, 5, 8995-9006.	1.8	10
124	Clinical-grade functional dendritic cells from patients with multiple myeloma are not infected with Kaposi's sarcoma-associated herpesvirus. Blood, 1998, 91, 1852-7.	1.4	10
125	ING1b negatively regulates HIF1α protein levels in adipose-derived stromal cells by a SUMOylation-dependent mechanism. Cell Death and Disease, 2015, 6, e1612-e1612.	6.3	9
126	IFN-γ, Unlike TNF-α, LPS, or CD40 Signal, Is Required and Sufficient To Induce Indoleamine 2,3-Dioxygenase Activity in Mesenchymal Stem Cells Blood, 2005, 106, 2311-2311.	1.4	8

#	Article	IF	CITATIONS
127	Bone Marrow Lymphoid Niche Adaptation to Mature B Cell Neoplasms. Frontiers in Immunology, 2021, 12, 784691.	4.8	8
128	Peripheral phenotype and gene expression profiles of combined liver–kidney transplant patients. Liver International, 2016, 36, 401-409.	3.9	7
129	Early-stage myeloid-derived suppressor cell count: Basophil exclusion matters. Journal of Allergy and Clinical Immunology, 2019, 144, 1125-1127.	2.9	7
130	Human Lymphoid Stromal Cells Contribute to Polarization of Follicular T Cells Into IL-4 Secreting Cells. Frontiers in Immunology, 2020, 11, 559866.	4.8	7
131	Committed Human CD23-Negative Light-Zone Germinal Center B Cells Delineate Transcriptional Program Supporting Plasma Cell Differentiation. Frontiers in Immunology, 2021, 12, 744573.	4.8	7
132	Histamine quantification in human plasma using high resolution accurate mass LC–MS technology. Clinical Biochemistry, 2016, 49, 111-116.	1.9	6
133	Generation of virtually pure and potentially proliferating dendritic cells from non-CD34 apheresis cells from patients with multiple myeloma. Blood, 1997, 90, 3482-95.	1.4	6
134	Impact of Chronic Viral Infection on T-Cell Dependent Humoral Immune Response. Frontiers in Immunology, 2017, 8, 1434.	4.8	5
135	High-Dimensional Phenotyping of Human Myeloid-Derived Suppressor Cells/Tumor-Associated Macrophages in Tissue by Mass Cytometry. Methods in Molecular Biology, 2021, 2236, 57-66.	0.9	5
136	PIM2 kinase has a pivotal role in plasmablast generation and plasma cell survival, opening up novel treatment options in myeloma. Blood, 2022, 139, 2316-2337.	1.4	5
137	CD40L-expressing CD4+ T cells prime adipose-derived stromal cells to produce inflammatory chemokines. Cytotherapy, 2022, 24, 500-507.	0.7	5
138	Nonclassical Monocytes Are Prone to Migrate Into Tumor in Diffuse Large B-Cell Lymphoma. Frontiers in Immunology, 2021, 12, 755623.	4.8	5
139	Response to Reinhardt <i>et al.</i> . Human Gene Therapy, 2011, 22, 776-776.	2.7	4
140	Blood Soluble PD-L1 Protein In Aggressive Diffuse Large B-Cell Lymphoma Impacts patient's Overall Survival. Blood, 2013, 122, 361-361.	1.4	4
141	Follicular Lymphoma-Like B Cells In Healthy Individuals Are Released From Pretumoral Niches Established In Secondary Lymphoid Tissues. Blood, 2010, 116, 466-466.	1.4	4
142	The flawless immune tolerance of pregnancy. Joint Bone Spine, 2021, 88, 105205.	1.6	3
143	Iterative Germinal Center Re-Entries of Memory B-Cells with t(14;18) Translocation and Early Steps of Follicular Lymphoma Progression. Blood, 2012, 120, 150-150.	1.4	3
144	Lenalidomide Treatment Restores In Vivo T Cell Activity in Relapsed/Refractory FL and DLBCL. Blood, 2017, 130, 729-729.	1.4	3

#	Article	IF	CITATIONS
145	Immunomodulatory antibodies for the treatment of lymphoma: Report on the CALYM Workshop. Oncolmmunology, 2016, 5, e1186323.	4.6	2
146	GENE-EXPRESSION PROFILING PREDICTS DISEASE PROGRESSION IN FOLLICULAR LYMPHOMA. Hematological Oncology, 2017, 35, 113-115.	1.7	2
147	Neutrophil function and bactericidal activity against <i>Staphylococcus aureus</i> after cardiac surgery with cardiopulmonary bypass. Journal of Leukocyte Biology, 2022, 111, 867-876.	3.3	2
148	Gene Expression Profiling of Highly Purified Malignant and Non-Malignant Cells: Characterization of the Tumor-Microenvironment Cellular Synapse in De Novo Follicular Lymphoma (FL) Blood, 2007, 110, 355-355.	1.4	2
149	DC-SIGN Binds Preferentially Highly Glycosylated IgM to Trigger Classical BCR Signaling in Follicular Lymphoma. Blood, 2014, 124, 2968-2968.	1.4	2
150	Le myélome multiple : un nouveau cancer induit par un virus ?. Medecine/Sciences, 1998, 14, 736.	0.2	2
151	Kaposi's sarcoma-associated herpesvirus is not detected with immunosuppression in multiple myeloma. Blood, 1998, 92, 2186-8.	1.4	2
152	Le polynucléaire basophile: nouveautés en physiopathologie et implications diagnostiques. Revue Francophone Des Laboratoires, 2014, 2014, 95-105.	0.0	1
153	Microporous Biphasic Calcium Phosphate Granules (MBCP®) Retain Immunological Properties of Bone Marrow-Derived Mesenchymal Stromal Cells and Promote Osteoblastic Differentiation. Blood, 2011, 118, 1924-1924.	1.4	1
154	Emergence of Long-Lived Autoreactive Plasma Cells in the Spleen of Primary Warm Auto-Immune Hemolytic Anemia Patients Treated with Rituximab. Blood, 2014, 124, 569-569.	1.4	1
155	T-Cell Defect in Diffuse Large B-Cell Lymphomas Involves Expansion of Myeloid Derived Suppressor Cells Expressing IL-10, PD-L1, and S100A12. Blood, 2015, 126, 1478-1478.	1.4	1
156	The EHA Research Roadmap: Malignant Lymphoid Diseases. HemaSphere, 2022, 6, e726.	2.7	1
157	Genomic stability in clinical scale expanded mesenchymal stem/stromal cells. ISBT Science Series, 2010, 5, 212-212.	1.1	0
158	92: Bone Marrow Mesenchymal Stem Cells are altered in CLL. Bulletin Du Cancer, 2010, 97, S75-S76.	1.6	0
159	2.43 Mesenchymal Progenitors from Chronic Lymphocytic Leukemia Bone Marrow Aspirates are Rare and Display an Altered Phenotype. Clinical Lymphoma, Myeloma and Leukemia, 2011, 11, S186-S187.	0.4	0
160	Effects of a novel ceramic biomaterial on immune modulatory properties and differentiation potential of mesenchymal stromal cells. Cytotherapy, 2014, 16, S90-S91.	0.7	0
161	Reply: Standardized procedure for bone marrow MSCs preparation for clinical use. Stem Cells, 2016, 34, 1994-1995.	3.2	0
162	Reply to Patel et al.: Tempering the Clinical Effects of Early Myeloid-derived Suppressor Cell Expansion in Severe Sepsis and Septic Shock. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 678-679.	5.6	0

#	Article	IF	CITATIONS
163	Un exemple de toléranceÂ: l'immunologie de la grossesse. Revue Du Rhumatisme Monographies, 2021, 88, 8-12.	0.0	0
164	Regulatory and Activated T Cells in Stem Cell Autografts Collected by Mobilization with High-Dose Cyclophosphamide and Granulocyte Colony Stimulating Factor Blood, 2005, 106, 5216-5216.	1.4	0
165	Human Mesenchymal Stem Cells as Precursors of Functional Fibroblastic Reticular Cells: Implications for the Physiopathology of Secondary Lymphoid Organs Blood, 2005, 106, 2310-2310.	1.4	0
166	CD40L Modulates TRAIL-Induced Apoptosis in Germinal Center Derived B Cell Lymphomas Blood, 2006, 108, 4630-4630.	1.4	0
167	Human Mesenchymal Stem Cells Isolated from Bone Marrow and Lymphoid Organs Support Tumor B-Cell Growth: Implications in Follicular Lymphoma Pathogenesis Blood, 2006, 108, 2409-2409.	1.4	0
168	Influence of Inflammatory Factors Produced during Graft-Versus-Host Disease on Immunological Properties of Mesenchymal Stem Cells (MSC) Blood, 2006, 108, 3241-3241.	1.4	0
169	Quantitative and Functional Alterations of the Gamma Delta T-Cell Subset within Follicular Lymphoma Microenvironment Blood, 2007, 110, 2601-2601.	1.4	0
170	Aneuploidy in Clinical-Grade Mesenchymal Stem Cells Is Not Linked to Cell Transformation and Not Related to Culture Method. Blood, 2008, 112, 3463-3463.	1.4	0
171	Bone Marrow Mesenchymal Stem Cells Are Altered in B-Cell Chronic Lymphocytic Leukemia Blood, 2008, 112, 2066-2066.	1.4	0
172	Follicular Lymphoma Cell Niche: Identification of a Preeminent IL-4-Dependent TFH- B Cell Axis Blood, 2009, 114, 757-757.	1.4	0
173	Mesenchymal Stromal Cells Orchestrate Follicular Lymphoma Cell Niche Through the CCL2-Dependent Recruitment and Polarization of Monocytes. Blood, 2011, 118, 1566-1566.	1.4	0
174	Quality Controls of Immune Regulatory Properties of Ex-Vivo, GMP-Grade Expanded Mesenchymal Stromal Cells for Clinical Use (European multicenter study CASCADE),. Blood, 2011, 118, 4049-4049.	1.4	0
175	Molecular Characterization of the Leukemic Niche in Chronic Myeloid Leukemia (CML) and Evaluation of a Leukemia / Niche Cross-Talk. Blood, 2012, 120, 908-908.	1.4	0
176	Effects Of a Novel Ceramic Biomaterial On Immune Modulatory Properties and Differentiation Potential Of Mesenchymal Stromal Cells. Blood, 2013, 122, 4858-4858.	1.4	0
177	Quality Controls Of Immune Regulatory Properties Of Ex-Vivo, GMP-Grade Expanded Mesenchymal Stromal Cells For Clinical Use. Blood, 2013, 122, 5413-5413.	1.4	0
178	Immune Regulatory Properties Are a Common Feature Of Stem Cells. Blood, 2013, 122, 5419-5419.	1.4	0
179	Pan-HDAC Inhibitors May Restore PRDM1 Expression in Follicular Lymphoma. Blood, 2018, 132, 2848-2848.	1.4	0
180	Niveau, a Phase 3 Study for Pts with B- or T-Cell Aggressive Non-Hodgkin Lymphoma in First Relapse or Progression Not Eligible for High-Dose Chemotherapy (HDT), Testing Nivolumab in Combination with Gemcitabine, Oxaliplatin (GemOx), Plus Rituximab (R) in Case of B-Cell Lymphoma. Blood, 2019, 134, 5311-5311.	1.4	0

#	Article	IF	CITATIONS
181	AB0034â€EARLY IMMUNIZATION AGAINST TREATMENT IS ASSOCIATED TO POOR CLINICAL RESPONSE AT 6 MONTHS AND LOW NUMBER OF TRANSITIONAL B CELLS AT BASELINE IN RHEUMATOID ARTHRITIS PATIENTS TREATED BY ADALIMUMAB. Annals of the Rheumatic Diseases, 2020, 79, 1319.1-1320.	0.9	0
182	Mass Cytometry and Artificial Intelligence Define CD169 as a Marker of SARS-CoV2-Induced Acute Respiratory Distress Syndrome, SSRN Electronic Journal, 0	0.4	0

Respiratory Distress Syndrome. SSRN Electronic Journal, 0, , . 182